RAP1GDS1 - Wiki-CORONA

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
ABCB7	ATP binding cassette subfamily B member 7	Mitochondrial ABC transporters Cytosolic iron-sulfur cluster assembly		Sideroblastic anemia, including: Pyridoxine-refractory autosomal recessive sideroblastic anemia (PRARSA); X-linked sideroblastic anemia (XLSA); X-linked sideroblastic anemia with ataxia (ASAT)
ANTXR2	ANTXR cell adhesion molecule 2			Infantile systemic hyalinosis and juvenile hyaline fibromatosis
CDC42	cell division cycle 42	GPVI-mediated activation cascade EGFR downregulation Rho GTPase cycle Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation CD28 dependent Vav1 pathway EPHB-mediated forward signaling EPHB-mediated forward signaling DCC mediated attractive signaling Inactivation of CDC42 and RAC1 VEGFA-VEGFR2 Pathway Myogenesis Myogenesis RHO GTPases activate KTN1 RHO GTPases activate IQGAPs RHO GTPases activate PAKs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins MAPK6/MAPK4 signaling Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation G beta:gamma signalling through CDC42 FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis Factors involved in megakaryocyte development and platelet production	Aminophosphonic Acid-Guanylate Ester Guanosine-5'-Diphosphate
DOC2A	double C2 domain alpha
EGFR	epidermal growth factor receptor	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling Signaling by EGFR GRB2 events in EGFR signaling GAB1 signalosome SHC1 events in EGFR signaling EGFR downregulation GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling EGFR interacts with phospholipase C-gamma EGFR Transactivation by Gastrin Constitutive Signaling by Aberrant PI3K in Cancer Signal transduction by L1 Constitutive Signaling by EGFRvIII Inhibition of Signaling by Overexpressed EGFR RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis PTK6 promotes HIF1A stabilization Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Extra-nuclear estrogen signaling NOTCH3 Activation and Transmission of Signal to the Nucleus HCMV Early Events Estrogen-dependent nuclear events downstream of ESR-membrane signaling Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Alvocidib IGN311 Matuzumab Vandetanib Rindopepimut Canertinib Pelitinib Varlitinib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib Osimertinib Necitumumab Depatuxizumab mafodotin Icotinib Neratinib Zalutumumab Brigatinib Olmutinib	Choriocarcinoma Gastric cancer Bladder cancer Oral cancer Glioma Laryngeal cancer Cervical cancer Esophageal cancer
HRAS	HRas proto-oncogene, GTPase	SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth EPHB-mediated forward signaling Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS GTPase cycle mutants Signaling downstream of RAS mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants	Hexane-1,6-Diol Trifluoroethanol Guanosine-5'-Triphosphate Guanosine-5'-Diphosphate N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE	Bladder cancer Penile cancer Squamous cell carcinoma Thyroid cancer Cervical cancer Hepatocellular carcinoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
KIFAP3	kinesin associated protein 3	Translocation of SLC2A4 (GLUT4) to the plasma membrane MHC class II antigen presentation Intraflagellar transport COPI-dependent Golgi-to-ER retrograde traffic Kinesins Kinesins
KRAS	KRAS proto-oncogene, GTPase	Signaling by moderate kinase activity BRAF mutants Paradoxical activation of RAF signaling by kinase inactive BRAF RUNX3 regulates p14-ARF RAS GTPase cycle mutants Signaling downstream of RAS mutants	[(3,7,11-TRIMETHYL-DODECA-2,6,10-TRIENYLOXYCARBAMOYL)-METHYL]-PHOSPHONIC ACID FARNESYL DIPHOSPHATE	Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome Pancreatic cancer Gastric cancer Colorectal cancer Non-small cell lung cancer Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Oral cancer Acute myeloid leukemia (AML) Endometrial Cancer Multiple myeloma Squamous cell carcinoma Kaposi's sarcoma Cholangiocarcinoma Thyroid cancer Cervical cancer Hepatocellular carcinoma Ovarian cancer Gallbladder cancer
LEF1	lymphoid enhancer binding factor 1	Formation of the beta-catenin:TCF transactivating complex Formation of the beta-catenin:TCF transactivating complex Deactivation of the beta-catenin transactivating complex Ca2+ pathway Binding of TCF/LEF:CTNNB1 to target gene promoters Repression of WNT target genes Repression of WNT target genes Transcriptional Regulation by VENTX RUNX3 regulates WNT signaling Transcriptional regulation of granulopoiesis Transcriptional regulation of granulopoiesis	Etacrynic acid
MBIP	MAP3K12 binding inhibitory protein 1	HATs acetylate histones
MED28	mediator complex subunit 28	PPARA activates gene expression Transcriptional regulation of white adipocyte differentiation Transcriptional regulation of white adipocyte differentiation
NRAS	NRAS proto-oncogene, GTPase	SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Signaling by FGFR3 fusions in cancer Signaling by FGFR3 point mutants in cancer Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS GTPase cycle mutants Signaling downstream of RAS mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Oral cancer Acute myeloid leukemia (AML) Multiple myeloma Adrenal carcinoma Thyroid cancer Hepatocellular carcinoma Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS Malignant melanoma
PLEKHB1	pleckstrin homology domain containing B1
PTPRF	protein tyrosine phosphatase receptor type F	Receptor-type tyrosine-protein phosphatases Synaptic adhesion-like molecules
PUF60	poly(U) binding splicing factor 60	mRNA Splicing - Major Pathway
RAC1	Rac family small GTPase 1	GPVI-mediated activation cascade PIP3 activates AKT signaling Signaling by SCF-KIT Translocation of SLC2A4 (GLUT4) to the plasma membrane Nef and signal transduction NRAGE signals death through JNK Rho GTPase cycle Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling FCERI mediated MAPK activation DSCAM interactions CD28 dependent Vav1 pathway EPHB-mediated forward signaling Ephrin signaling EPH-ephrin mediated repulsion of cells Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion PCP/CE pathway Sema4D mediated inhibition of cell attachment and migration DCC mediated attractive signaling DCC mediated attractive signaling Activation of RAC1 Inactivation of CDC42 and RAC1 VEGFA-VEGFR2 Pathway Signal transduction by L1 VEGFR2 mediated vascular permeability RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases activate IQGAPs RHO GTPases activate PAKs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins RHO GTPases Activate NADPH Oxidases MAPK6/MAPK4 signaling Neutrophil degranulation PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAP1 and RAC1 NTRK2 activates RAC1 Activated NTRK2 signals through CDK5 Activation of RAC1 downstream of NMDARs FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis WNT5:FZD7-mediated leishmania damping Factors involved in megakaryocyte development and platelet production	Dextromethorphan Azathioprine Guanosine-5'-Diphosphate
RAP1A	RAP1A, member of RAS oncogene family	Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation ARMS-mediated activation Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Rap1 signalling MAP2K and MAPK activation Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF MET activates RAP1 and RAC1 Signaling downstream of RAS mutants
RHOA	ras homolog family member A	GPVI-mediated activation cascade Axonal growth inhibition (RHOA activation) Rho GTPase cycle PI3K/AKT activation Axonal growth stimulation TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) G beta:gamma signalling through PI3Kgamma EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse PCP/CE pathway G alpha (12/13) signalling events Sema4D mediated inhibition of cell attachment and migration Sema4D induced cell migration and growth-cone collapse Sema4D induced cell migration and growth-cone collapse VEGFA-VEGFR2 Pathway RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases Activate ROCKs RHO GTPases Activate ROCKs RHO GTPases Activate Formins RHO GTPases Activate Rhotekin and Rhophilins RHO GTPases Activate Rhotekin and Rhophilins Ovarian tumor domain proteases ERBB2 Regulates Cell Motility Neutrophil degranulation PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases SLIT2:ROBO1 increases RHOA activity	Guanosine-5'-Diphosphate
ZNF451	zinc finger protein 451

Search Results for: RAP1GDS1